Sysmex Corporation (SSMXY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sysmex Corporation (SSMXY) trades at $9.74 with AI Score 48/100 (Grade C). Sysmex Corporation develops, manufactures, and sells diagnostic instruments, reagents, and software, primarily in Japan. Market cap: $6.05B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for SSMXY: SSMXY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SSMXY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SSMXY: the 1 perspectives are evenly split.
How is this calculated? →Sysmex Corporation (SSMXY) Healthcare & Pipeline Overview
Sysmex Corporation, a global leader in medical diagnostics, specializes in hematology, immunochemistry, and flow cytometry solutions. With a strong presence in Japan and exports to 190 countries, Sysmex provides instruments, reagents, and software to hospitals and research institutions, driven by innovation and strategic alliances.
What Is the Investment Thesis for SSMXY?
Sysmex Corporation presents a compelling investment case based on its established market position, consistent profitability, and strategic focus on innovation in medical diagnostics. With a P/E ratio of 24.7 and a profit margin of 8.9%, Sysmex demonstrates financial stability. Growth catalysts include expanding its product offerings in cancer diagnostics and digital medicine, as well as leveraging its global presence to penetrate emerging markets. The company's dividend yield of 2.42% provides an additional incentive for investors. Potential risks include increasing competition in the diagnostics market and fluctuations in currency exchange rates, given its significant international operations. The company's beta of 0.66 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
SSMXY Key Highlights
- Market capitalization of $6.05B, reflecting its significant presence in the medical diagnostics market.
- P/E ratio of 24.7, indicating a reasonable valuation relative to its earnings.
- Profit margin of 8.9%, demonstrating solid profitability in a competitive industry.
- Gross margin of 51.9%, showcasing efficient cost management in its manufacturing and sales operations.
- Dividend yield of 2.42%, providing a steady income stream for investors.
Who Are SSMXY's Competitors?
SSMXY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVVF ConvaTec Group Plc | $2.73 | +0.00% | $5.32B | 49 |
| CNVVY ConvaTec Group Plc | $11.74 | +0.41% | $5.74B | 43 |
| FLMNF Fielmann AG | $52.85 | +4.14% | $4.44B | 50 |
| KYKOF Kyowa Kirin Co., Ltd. | $14.20 | -1.56% | $7.43B | 57 |
| MSMKF MatsukiyoCocokara & Co. | $14.60 | +0.00% | $5.74B | 49 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SSMXY's Key Strengths?
- Strong global presence with exports to approximately 190 countries.
- Diverse product portfolio spanning hematology, immunochemistry, and flow cytometry.
- Strategic alliance with QIAGEN N.V. for cancer companion diagnostics.
- Consistent profitability and solid financial performance.
What Are SSMXY's Weaknesses?
- Reliance on the Japanese market for a significant portion of its revenue.
- Exposure to currency exchange rate fluctuations.
- Limited presence in certain emerging markets.
- Dependence on key suppliers for critical components and materials.
What Could Drive SSMXY Stock Higher?
- Expansion of cancer diagnostics product line, driven by strategic alliance with QIAGEN N.V., enhancing market position and revenue potential.
- Growth in digital medicine solutions, leveraging IT expertise to capitalize on the increasing demand for digital health technologies.
- Penetration of emerging markets, particularly in Asia-Pacific and Latin America, where healthcare spending is rapidly increasing.
- Development of innovative medical robots and automation solutions, improving the efficiency and accuracy of diagnostic procedures.
- Expansion of reagent offerings for emerging diagnostic applications, such as liquid biopsy and personalized medicine, differentiating from competitors.
What Are the Key Risks for SSMXY?
- Increasing competition in the medical diagnostics market, potentially impacting market share and profitability.
- Regulatory changes and healthcare reforms, which could affect pricing and reimbursement for diagnostic tests.
- Economic downturns and reduced healthcare spending, leading to decreased demand for diagnostic products and services.
- Technological obsolescence and the need for continuous innovation, requiring significant investment in research and development.
- Currency exchange rate fluctuations, given its significant international operations, affecting revenue and profitability.
What Are the Growth Opportunities for SSMXY?
- Expansion in Cancer Diagnostics: Sysmex has a significant opportunity to expand its presence in cancer diagnostics through its cancer lymph node metastasis testing systems and cancer genome profiling systems. The global cancer diagnostics market is projected to reach $25 billion by 2027. Sysmex's strategic alliance with QIAGEN N.V. further strengthens its position in this market, providing a competitive edge through the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. This collaboration enhances Sysmex's ability to offer comprehensive solutions for cancer detection and treatment.
- Growth in Digital Medicine: Sysmex is actively involved in the development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine. The digital health market is expected to reach $660 billion by 2025. By leveraging its expertise in diagnostic information systems, Sysmex can capitalize on the increasing demand for digital health solutions that improve patient outcomes and streamline healthcare delivery. This includes developing software for diagnostic information systems and providing IT solutions for healthcare facilities.
- Penetration of Emerging Markets: Sysmex exports its products to approximately 190 countries, indicating a strong global presence. However, there is significant potential to further penetrate emerging markets, particularly in Asia-Pacific and Latin America, where healthcare spending is rapidly increasing. By tailoring its product offerings to meet the specific needs of these markets and establishing strategic partnerships with local distributors, Sysmex can drive revenue growth and expand its market share. This includes offering cost-effective diagnostic solutions and providing training and support to healthcare professionals in these regions.
- Development of Medical Robots: Sysmex is involved in the marketing, development, design, manufacture, sale, and after-sales service related to medical robots. The medical robotics market is projected to reach $20 billion by 2027. By leveraging its expertise in medical technology and automation, Sysmex can develop innovative robotic solutions that improve the efficiency and accuracy of diagnostic procedures. This includes developing robots for sample preparation, automated testing, and other laboratory tasks.
- Expansion of Reagent Offerings: Sysmex offers a wide range of reagents for use in its diagnostic instruments. There is an opportunity to expand its reagent offerings to include new and improved reagents that enhance the performance and accuracy of its diagnostic tests. By investing in research and development to develop innovative reagents, Sysmex can differentiate itself from competitors and capture a larger share of the reagent market. This includes developing reagents for emerging diagnostic applications, such as liquid biopsy and personalized medicine.
What Opportunities Does SSMXY Have?
- Expansion in cancer diagnostics and digital medicine.
- Penetration of emerging markets with increasing healthcare spending.
- Development of innovative medical robots and automation solutions.
- Expansion of reagent offerings for emerging diagnostic applications.
What Threats Does SSMXY Face?
- Increasing competition in the medical diagnostics market.
- Regulatory changes and healthcare reforms.
- Economic downturns and reduced healthcare spending.
- Technological obsolescence and the need for continuous innovation.
What Are SSMXY's Competitive Advantages?
- Established brand reputation and long-standing relationships with key customers.
- Proprietary technology and intellectual property in diagnostic instruments and reagents.
- Extensive global distribution network, reaching approximately 190 countries.
- Strategic alliances with companies like QIAGEN N.V. to enhance its product offerings.
What Does SSMXY Do?
Founded in 1968 as TOA Medical Electronics Co., Ltd., Sysmex Corporation has evolved into a leading developer, manufacturer, and distributor of diagnostic instruments, reagents, and related software. Headquartered in Kobe, Japan, the company changed its name to Sysmex Corporation in October 1998, marking a shift towards a more global and integrated approach to healthcare solutions. Sysmex's core offerings include hematology analyzers, such as three-part and five-part white blood cell differentiation instruments, used for high-volume testing in laboratories. The company also provides urine formed sediment analysis systems and automated immunochemistry systems that perform assays on minute sample quantities. These systems are complemented by a range of reagents used to test for infectious diseases and tumor markers. Sysmex's flow cytometry solutions are essential for diagnosing leukemia, malignant lymphoma, and HIV/AIDS. Furthermore, Sysmex develops and markets cancer lymph node metastasis testing systems, cancer genome profiling systems, and cytogenic testing and lab assay services. The company is also involved in developing software for diagnostic information systems and offers facility management, office, and welfare services. Sysmex serves a diverse customer base, including national and public hospitals, private hospitals, universities, research institutes, and other medical institutions. Its strategic alliance with QIAGEN N.V. focuses on developing and commercializing cancer companion diagnostics, leveraging Plasma-Safe-SeqS technology.
What Products and Services Does SSMXY Offer?
- Develops and manufactures diagnostic instruments for hematology analysis.
- Produces reagents used in various diagnostic testing procedures.
- Creates software for diagnostic information systems.
- Offers automated immunochemistry systems for sample analysis.
- Provides flow cytometers for diagnosing blood disorders and immune deficiencies.
- Develops cancer lymph node metastasis testing systems.
- Offers cancer genome profiling systems and cytogenic testing services.
- Engages in the development of IT solutions for digital medicine.
How Does SSMXY Make Money?
- Sales of diagnostic instruments to hospitals, research institutions, and medical facilities.
- Recurring revenue from the sale of reagents used in conjunction with its instruments.
- Software licensing and maintenance fees for its diagnostic information systems.
- Service and support contracts for its installed base of instruments.
What Industry Does SSMXY Operate In?
Sysmex Corporation operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced diagnostic solutions. The global medical devices market is projected to reach $600 billion by 2028, driven by an aging population, rising prevalence of chronic diseases, and technological advancements. Sysmex competes with companies like CNVVF (bioMérieux), CNVVY (bioMerieux SA), FLMNF (Faron Pharmaceuticals), KYKOF (Koninklijke Philips NV), and MSMKF (Medismart Co Ltd) in various segments of the diagnostics market. Sysmex's focus on hematology, immunochemistry, and flow cytometry positions it to capitalize on the growing demand for accurate and efficient diagnostic testing.
Who Are SSMXY's Key Customers?
- National and other public hospitals.
- Private hospitals and clinics.
- Universities and research institutes.
- Other medical institutions.
Company Profile
Sysmex Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Kobe, JP. The company is led by CEO Hisashi Ietsugu. SSMXY has traded publicly since 2011.
How Sysmex Corporation Is Valued
Sysmex Corporation carries a market capitalization of $6.05B, placing it in the mid-cap category. Relative to its peer group, SSMXY's quantitative score of 48/100 is roughly in line with the peer average of 50/100.
ROE 7%Key Financial Metrics
Return on equity for Sysmex Corporation stands at 7.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.0%, showing how much profit it generates from its asset base. SSMXY trades at a trailing price-to-earnings ratio of 24.69, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 4.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.26 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Sysmex Corporation's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.11 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Sysmex Corporation revenue of about $502.73B for fiscal 2026, with EPS near $64.58. The estimate reflects 8 contributing analysts.
SSMXY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Sysmex's future performance, indicating that leadership believes in the company's growth potential.
- Community sentiment has shifted positively, with discussions highlighting Sysmex's innovations in diagnostic technology and their impact on healthcare.
- The ongoing demand for advanced diagnostic solutions positions Sysmex favorably in a growing market, attracting positive investor interest.
- Recent partnerships with healthcare providers enhance Sysmex's market presence, reinforcing its reputation as a leader in the diagnostics field.
Bear Case
- Concerns about global supply chain disruptions may impact Sysmex's ability to meet growing demand, leading to potential operational challenges.
- Bearish sentiment in the community reflects worries about increased competition in the diagnostics sector, which could pressure market share.
- Recent regulatory changes in key markets have raised uncertainty about Sysmex's product approvals, leading to cautious investor sentiment.
- Market perception is clouded by economic factors affecting healthcare spending, creating hesitance among investors regarding Sysmex's growth trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SSMXY Latest News
-
Japan In Vitro Diagnostics Market Research Trends and Forecast Report 2026-2035 Featuring, Abbott Laboratories, Arkray, Danaher, Fujirebio, H.U., Roche Diagnostics, Sysmex, Tosoh
Yahoo! Finance: SSMXY News · May 18, 2026
-
Sysmex Sees FY2026 GAAP EPS $0.37 vs $0.44 Est; Sees Sales $3.411B vs $3.140B Est
benzinga · May 14, 2026
-
Sysmex Q4 EPS $0.01 Down From $0.06 YoY, Sales $885.231M Down From $929.632M YoY
benzinga · May 14, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
SSMXY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SSMXY.
Price Targets
Wall Street price target analysis for SSMXY.
SSMXY MoonshotScore
What does this score mean?
The MoonshotScore rates SSMXY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Japan In Vitro Diagnostics Market Research Trends and Forecast Report 2026-2035 Featuring, Abbott Laboratories, Arkray, Danaher, Fujirebio, H.U., Roche Diagnostics, Sysmex, Tosoh
Sysmex Sees FY2026 GAAP EPS $0.37 vs $0.44 Est; Sees Sales $3.411B vs $3.140B Est
Sysmex Q4 EPS $0.01 Down From $0.06 YoY, Sales $885.231M Down From $929.632M YoY
Stocks That Hit 52-Week Lows On Tuesday
Leadership: Hisashi Ietsugu
Unknown
Information about Hisashi Ietsugu's background is not available in the provided context. Therefore, a detailed biography cannot be provided. His professional history, education, and previous roles remain unknown.
Track Record: Information about Hisashi Ietsugu's track record is not available in the provided context. Therefore, a summary of his key achievements, strategic decisions, and company milestones under his leadership cannot be provided.
Sysmex Corporation ADR Information Unsponsored
An American Depositary Receipt (ADR) like SSMXY represents shares of a non-U.S. company (Sysmex Corporation) held by a U.S. depositary bank. It allows U.S. investors to trade shares of foreign companies on U.S. exchanges, simplifying the process and reducing complexities associated with international investing. SSMXY is an over-the-counter (OTC) ADR.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SSMX
SSMXY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sysmex Corporation (SSMXY) has limited or no reporting requirements with U.S. regulators. Unlike companies listed on the NYSE or NASDAQ, OTC Other companies often do not adhere to strict listing standards or financial reporting requirements. This tier is considered the most speculative due to the limited information available to investors and the potential for higher risk.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial reporting requirements, making it difficult to assess the company's financial health.
- Lack of regulatory oversight, increasing the risk of fraud or mismanagement.
- Low trading volume and liquidity, potentially leading to price volatility and difficulty in executing trades.
- Limited availability of company information, making it challenging to conduct thorough due diligence.
- Higher risk of delisting or suspension of trading due to non-compliance with regulatory requirements.
- Verify the company's registration and legal status.
- Obtain and review any available financial reports or company information.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor to assess the suitability of the investment.
- Monitor the company's news and announcements for any updates or developments.
- The company has been in operation since 1968.
- Sysmex has a market capitalization of $6.05B.
- Sysmex exports its products to approximately 190 countries.
- Sysmex has a strategic alliance with QIAGEN N.V.
- Sysmex is a well-established company in Japan.
Common Questions About SSMXY (Healthcare)
What does Sysmex Corporation do?
Sysmex Corporation is a global leader in the development, manufacture, and sale of diagnostic instruments, reagents, and software. The company's core business revolves around providing solutions for in-vitro diagnostics, primarily in the fields of hematology, immunochemistry, and flow cytometry. Sysmex's products are used by hospitals, research institutions, and other medical facilities to analyze blood, urine, and other bodily fluids, aiding in the diagnosis and monitoring of various diseases and conditions. The company also offers cancer lymph node metastasis testing systems and cancer genome profiling systems.
What are the main risks for SSMXY?
The main risks for Sysmex Corporation include increasing competition in the medical diagnostics market, which could put pressure on pricing and market share. Regulatory changes and healthcare reforms could also impact the company's revenue and profitability. Additionally, economic downturns and reduced healthcare spending could lead to decreased demand for diagnostic products and services. Technological obsolescence is another risk, requiring continuous investment in research and development to maintain a competitive edge. Currency exchange rate fluctuations also pose a risk, given the company's significant international operations.
What are the key factors to evaluate for SSMXY?
Sysmex Corporation (SSMXY) holds an AI score of 48/100 (low). P/E: 24.7x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does SSMXY data refresh on this page?
SSMXY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SSMXY's recent stock price performance?
Sysmex Corporation (SSMXY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong global presence with exports to approximately 190 countries. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SSMXY overvalued or undervalued right now?
Sysmex Corporation (SSMXY) trades at 24.7x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SSMXY?
Before investing in Sysmex Corporation (SSMXY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SSMXY to a portfolio?
Key strength of Sysmex Corporation (SSMXY): Strong global presence with exports to approximately 190 countries. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may have limited availability and accuracy.